GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Accumulated Depreciation

MindBio Therapeutics (XCNQ:MBIO) Accumulated Depreciation : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.


MindBio Therapeutics Accumulated Depreciation Historical Data

The historical data trend for MindBio Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Accumulated Depreciation Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Accumulated Depreciation
- - -

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MindBio Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


MindBio Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023